Abstract
Traumatic brain injury (TBI) initiates a complex cascade of secondary neurodegenerative mechanisms contributing to cell dysfunction and necrotic and apoptotic cell death. The injured brain responds by activating endogenous reparative processes to counter the neurodegeneration or remodel the brain to enhance functional recovery. A vast array of genetically altered mice provide a unique opportunity to target single genes or proteins to better understand their role in cell death and endogenous repair after TBI. Among the earliest targets for transgenic and knockout studies in TBI have been programmed cell death mediators, such as the Bcl-2 family of proteins, caspases, and caspase-independent pathways. In addition, the role of cell cycle regulatory elements in the posttraumatic cell death pathway has been explored in mouse models. As interest grows in neuroplasticity in TBI, the use of transgenic and knockout mice in studies focused on gliogenesis, neurogenesis, and the balance of growth-promoting and growth-inhibiting molecules has increased in recent years. With proper consideration of potential effects of constitutive gene alteration, traditional transgenic and knockout models can provide valuable insights into TBI pathobiology. Through increasing sophistication of conditional and cell-type specific genetic manipulations, TBI studies in genetically altered mice will be increasingly useful for identification and validation of novel therapeutic targets.
Original language | English |
---|---|
Pages (from-to) | 323-337 |
Number of pages | 15 |
Journal | Neurotherapeutics |
Volume | 9 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2012 |
Bibliographical note
Funding Information:This work was supported by grants from the National Institutes of Health (NS058484 and NS072302 to KES, and NS071804 to KMS), and the Kentucky Spinal Cord and Head Injury Research Trust (6-12 and 7-20 to KES). Full conflict of interest disclosures are available in the electronic supplementary material for this article.
Funding
This work was supported by grants from the National Institutes of Health (NS058484 and NS072302 to KES, and NS071804 to KMS), and the Kentucky Spinal Cord and Head Injury Research Trust (6-12 and 7-20 to KES). Full conflict of interest disclosures are available in the electronic supplementary material for this article.
Funders | Funder number |
---|---|
National Institutes of Health (NIH) | NS072302, NS058484 |
National Institute of Neurological Disorders and Stroke | F31NS071804 |
Kentucky Spinal Cord and Head Injury Research Trust | 6-12, 7-20 |
Keywords
- Apoptosis
- Growth factors
- Knockout mice
- Neurogenesis
- Neuroplasticity
- Transgenic mice
ASJC Scopus subject areas
- Pharmacology
- Clinical Neurology
- Pharmacology (medical)